"The FDA clearance of ACE723 marks an important milestone for our AD2C platform and brings our first AD2C-generated candidate into clinical development," said Sonny Hsiao, Ph.D., Chief Executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results